Contemporary analyses of the osteosarcoma microenvironment underscore the abundance of myeloid populations, the scarcity and dysfunction of effector T cells, and stromal programs that collectively blunt antitumor immunity (7–9), framing a setting in which neurotrophin signaling could recalibrate leukocyte behavior and treatment responsiveness. The gene discussed is BDNF; the disease is osteosarcoma.